Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The news always comes up about 45 minutes into trading at around 7:15 AM so there will be a spike at the open. I anticipate some news regarding the status on Monday or Tuesday.
You will be missing out on partnership PRs and the second FDA application which will be imminent once the first FDA approval comes through. Always keep some shares for more boomage.
DECN once approved will help more people go back to work and travel.
Here is the link to all the documents filed today which includes Annual Report for 2019 and 2018 and the supplemental information
https://www.otcmarkets.com/stock/DECN/disclosure
Who will need this testing in 3 months from now?
Many places even after the 1st and 2nd wave is over- churches, cruise ships, airports any congregation really.How would you trust in a group setting that no one is contaminated? Right now they use heat sensing for fevers which is not a good method at all.
Will vaccines will come to everyone's bloodstream very quickly? This year?
Can't rush the due process for vaccines unfortunately without testing it thoroughly.It is highly risky if they get it wrong so a year is the earliest estimate. when the vaccines come out they will have to be administered to everyone to eradicate SARS-COV-2 .How long will that take? maybe Q2 or Q3 next year.
Yeah so the previous sell signal for DECN on there was at 0.287c on 03/09 and that was a massive fail.
Genviro with its 15 second testing could be used for air travel pre boarding any flight and also on arrival for international travel. Genviro enables fast and efficient testing.This has potential to recover the air travel industry months in advance.
Serology test is one method and the most mainstream method for virus detection that have guidelines stated in the FDA EUA Policy.The SARS-COV-2 virus detection test is not required to be a Serology test. Serology tests have lower sensitivity ,lower accuracy and are slower than the Nonlinear electrical impedance spectroscopy of viruses that DECN is using to detect the virus.
Excerpts from the Nonlinear electrical impedance spectroscopy of viruses whitepaper - technology behind Gen-viro
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
"two key potential advantages: the ability to continuously monitor the environment, and to detect unspecified viruses and mutants, since biological information on genomes or receptors is not required"
"The results nevertheless show that the proposed nonlinear impedance spectroscopy method may achieve a sensitivity comparable to that of PCR and immunodetection systems"
1. Drug trials has nothing to do with the unmet testing needs
2. You contradict yourself when you say big pharma will get into testing. Why would they get in now if you believe that testing kits will not be required after Q1 2021 once vaccine magically gets into the bloodstream of every human on Earth?
3. FDA denying the application is just your opinion that will not happen if DECN meets their requirements.
Ok Bud I read the FDA policy for Diagnostic test for COVID-19 and it has the following mentioned
"FDA encourages test developers to discuss any alternative technological
approaches with FDA through CDRH-EUA-templates@FDA.HHS.GOV ".
Nowhere in the document do they mention that other methods are not allowed.Detection through electrical properties is not out of scope for COVID-19 testing.
Read the policy here
https://www.fda.gov/media/135659/download
No way! I thought DECN was trading at $200 and has 1000 DECN stores all over the world. Of course there are ifs which is why this is trading at 13c. The 525 million kits are not priced in nor does the FDA approval or the fact that they got a 13MM loan. Only thing priced in is the Pending FDA status and that its in a CV sector.
"The manufacturing facility needs to be constructed". Where did you see this line? This is laughable if they are planning to build a new facility for this.The kits will be licensed if they cannot produce it post approval so no they don't have to personally manufacture the units. If this kit does what it says there wont be a problem in making these. Every door out there would open for them.
"if a COVID-19 vaccine is perfected by the first quarter of next year, DECN is in trouble" .No one knows how long before this vaccine is available.Can you imagine the lines to administer this vaccine to say 2 to 3 Billion or even 100 Million people within 3 months? Vaccines are needed but its not a quick fix to this situation by any means.
The bottom line is we that need this and other tests for the next 1 to 2 years to test ourselves and trust others. There will be high demand once FDA approval kicks in and the 525 million kits can be produced by licensing as well. Several manufacturing facilities will be willing in a heartbeat to produce these kits.
Its not proven yet that the device works for COVID19 and the current pps reflects that.This is the unknown every other conspiracy theory out there is noise and fiction.The risk reward here is astounding.
This kind of test is absolutely imperative in this post COVID19 world not just for testing when you feel sick but just ask yourself this question -Would you let a plumber or an electrician come in your house or let a caretaker take care of your baby or elderly without this kind of test? This kind of quick test would be the lifeline for so many social oriented jobs in the next couple of years. People who applied for lower mortgage rates would you be ok with letting the appraiser come in and touch and breathe on every part of your house.Stay safe and hope every test kit out there is approved and manufactured in large numbers.
I am still holding my ton of warrants and some shares. I think we should see a upward trend till April and I am waiting to sell all my shares and up to half my warrants when the US FDA news comes in. This one really made me move out of stocks and in to crypto early last year and I am much happier with my current investments.I am worried that no one believes in Dario and traders only look at spikes as a shorting opportunity.
I have a feeling that they are trying to time it with the Android FDA approval. Both news together can really pick up the pps.
The numbers are going to be great so I am not worried about the statement.
As DRIO moves up take a look at the warrants DRIOW to maximize your profit. Dario is at a state now where the pps should be in the range of 6 - 10 bucks and could be higher once they get their Android and iPhone 7 approval in the US which is due early this year.Best of Luck!
They executed the financing round well this time.
Dariohealth is taking way too long and the FDA approval process is slow as a snail.
They announced lightning port option as soon as Iphone 7 was released but it looks like its still in preliminary design stages and wont hit the market before Iphone 8 or 9. They need to redesign their product soon.Its been 4 years since the original product came out.In summary the company needs to speed up their efforts overall to turn this around.I think they lack leadership and management skills and the CEO is an inexperienced moron.
There is no interest in this company and the management is not doing anything to generate any for reasons only known to them.For a direct marketing company they absolutely suck at marketing.None of their social media handles are actively promoting their product or generating buzz.
Dilution, RS and waiting for approvals seems to be their mantra.The Research team are slow in developing new features ,for example, they have not fixed the display resolution for large screen phones.
There is no need to look here till much after the next dilution in March 2017.This is going to drift lower.
Someone on twitter posted a picture of Dario working with his IPhone 7 plus with the adapter.
https://twitter.com/denisvr/status/781191290302201856
Dario announces Worlds first iphone 7 compatible mobile glucose meter
http://www.phonearena.com/news/Dario-Health-announces-worlds-first-iPhone-7-compatible-mobile-glucose-meter_id85182
Just saw this on twitter
Cannot confirm if it is true but its from a tech analyst
Headphones aren't the only thing using the #iPhone7 Lightning connector. How about a glucose monitor from @my_dario pic.twitter.com/0TjUMvLRe6
— Kurt Marko (Live long and prosper 🖖) (@krmarko) September 7, 2016
Everyone knows earnings will be good compared to last quarter or last year .It is expected. They need to give something more to move north of $6. They need to show business growth and expansion not just sequential YOY revenues.
For a social media marketing company they have no social media presence. If the CEO, VP and employees don't promote the product then who will.
No word on Android approval in US after more than 6 months.
No word on launch in the new countries targeted for 2016.
No word on insurance reimbursement status in US.
No word on new features in the app.
No word on compatibility for new Android devices.
No word on the product featured on amazon store.
No word period.
All they have PR'd in the last 2 months are attending investor conference and become a member of a NPO (and they paid money to become a member).These PRs are a waste of money.
I think they have employed a bunch of losers including the CEO that have no business expertise.
Of course they will show sequential growth but its of no use if the stock price remains stagnant.It will only move downward.
Labstyle seems to me is in the business of raising money, diluting and giving the management raises for no reason.
Rodman & Renshaw started coverage of LabStyle Innovations (DRIO) with a buy rating and a price target of 12 on 05/09/2016.
We should see a steady upside now through the earnings.
http://biotuesdays.com/2016/05/09/rodman-starts-labstyle-innovations-at-buy/
The parity ratio should be closer to 1.2 but I am happy with the $1.3 it is currently and I think it will fly with any news.
There are a number of things that the company needs to update us on to achieve a share price of $20. Some of them I can think of are:
1. Insurance reimbursement.
2. Android app approval in US.
3. Better payment setup and availability on Amazon store.
4. Rollout in the countries mentioned for 2016.
5. Start development of other or new products.
6. Better marketing strategy.(They are not good at social media marketing).
I feel that the company is slow in execution and this is the biggest risk on this ticker as time may run out for them.
Since the US rollout was almost at the end of the quarter I am not looking for astonishing numbers. Their subscription model is what will kick up the sales figure up a few notches but beyond the next quarter (Q2) it will depend on the above factors and the execution speed.
I am generally on top of things on this but if you have any information of labstyle's progress feel free to update on this board.
Its good to have a meaningful conversation rather than deal with a joker like Nirk. He is sometimes entertaining though.
I am going to start scaling out at $20 and then buy on dips and sell on pops while maintaining a lower core position. The leverage with the warrants is tremendous and getting in early will pay off big time!
I had to sell a big chunk of my shares to get into the warrants but I am very happy with my decision.
What is your target price on this?
DRIOW (warrants expiring March 2021)
I am heavily invested in DRIOW warrants to the tune of near about 50000 warrants .I am planning to sell these around the $20 range.
I started this board to discuss the huge potential of the DRIO warrants and leverage it possesses compared to the DRIO common stock.
Good luck to all fellow investors!!
I believe CFO's shares worth $ 500k were part of the $2.5M private placement.
Dario is available today for purchase in the US .Facebook page has the link where you can buy Dario now. Prices are very reasonable and they have a subscription model for purchasing the strips.We should see a PR coming soon!
http://usa.mydario.com/shop/
Uplist to Nasdaq typically takes 7-10 business days after RS. I hope they release the US launch news early next week.
DRIOD- A new update on this site shows that The S-1 registration statement is effective 3/3/16.
The Finra site posts the effective date at 3/4. It should open tomorrow under ticker DRIOD with starting price of $6.3. Good luck!
There is a reason why the stock is holding at 30c and not under 20c with the RS split news out already for days and the same reason will keep it from tanking post split.
Go figure the reasons..
Outstanding will be 4.97 MM with the new dilution post split. If all immediately convertible warrants at 125% are converted then it will be around 6.3 MM.
I see the 1:18 split on 01/03 as an event on Scottrade as well with the older pps .Maybe the split is end of day.Who knows anymore what the labstyle management is upto.
Typically the split follows the same day or next day after filing but there is the Nasdaq uplisting in this case which may not be in their control.
I think with the low float and NASDAQ uplist pps will go towards $10 post split,albeit not immediately.
My guess is that the company is trying hard to line up many things around the NASDAQ uplisting but they are failing in execution.Personally since I have holding for over a year,I will give them a few more days to get their act right to come up with the US release, NASDAQ and possibly some other news that we have not heard about yet.
Great News today!
US launch is by end of February. The annual report was due in March but they released it a month early to get it out of the way or the US launch news.
Annual Report (10-K) out . $823,000 in revenue for 2015
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=10718613&type=PDF&symbol=DRIO&companyName=LabStyle+Innovations+Corp&formType=10-K&dateFiled=2016-02-08&cik=0001533998
New corporate fact sheet summarizes the latest news and the potential for Labstyle. Interesting read for everyone!
http://mydario.investorroom.com/download/LSI+Company+Overview+Feb32016.pdf
Ok so here are a few updates and I am quoting some of these.
"In the United States we plan to commence commercialization once our devices and test strips are packaged and labeled according to FDA guidelines. We intend to generate demand through a digital direct to consumer campaign. Customers will initially be able to purchase the product directly through our e-store or via Amazon. Third party distribution channels are expected to go live through the first and second quarters of 2016 to facilitate a subscription-based service via our proprietary store. We also intend to continue to broaden our reach via distribution agreements with national and regional DME and pharmacy chains."
Labstyle is also launching Dario Lite in Italy in 2016 .
"In order to expand our global market reach in terms of smartphone support and lower pricing, we intend to expand our product offerings in three main areas: (1) we are developing Dario™ Lite, a less expensive version of our BGMS which includes the same blood glucose meter as our Dario™, offers a 50 strip vial holder, and excludes a lancing device, (2) we are developing Dario for additional models of smartphones that operate the Android operating system and which are not typically available in western countries, and (3) we plan to package strips in vials containing 50 strips versus the existing product that contains 25 strips. We believe these additional offerings will assist us in penetrating additional cost sensitive markets."
They plan to launch and monetize the DarioCare Diabetes management Platform in 2016. Also in pipeline is launch in India, Panama and Costa Rica in 2016.
Labstyle 510k number and decision summary. Took a long time but finally..
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K150817
http://www.accessdata.fda.gov/cdrh_docs/reviews/K150817.pdf
For New Investors please read the Dec 2015 investors presentation at
http://mydario.investorroom.com/download/Dario+overview+Investors+Dec+2015.pdf
Lots of great information.